GREY:SBIYF - Post by User
Post by
Horn1369on Feb 07, 2012 10:05pm
299 Views
Post# 19502931
Interesting read on SBS
Interesting read on SBS
|
|
Case Study: Fighting Diabetes and Cardiovascular Diseases
The plant technology of SemBioSys is focused on two critical health areas, diabetes and cardiovascular disease - both on the rise globally. The increasing incidence of diabetes (one new diagnosis every five seconds) is expected to almost double insulin demand over the next five to six years. By 2025, the incidence of diabetes is expected to increase to over 380 million cases world-wide. The main causes are the aging population and lifestyle choices. Developing countries, a relatively new market, also want greater access to affordably priced insulin.
SemBioSys is developing a new source of plant produced Biosimilar Human Insulin (SBS-1000) from genetically engineered safflower. Now, with successful completion of Phase I and II clinical trials, SBS-1000 has the potential to offer higher scalability and cost effective production compared to commercial insulin currently available.
| Cardiovascular diseases, including heart attack and stroke, are the leading causes of mortality in developed nations. By 2010, this disease is projected to become the leading cause of mortality worldwide. Cardiovascular disease is caused by plaque build-up in blood vessels. Based on clinical results, patients require large doses, this factor combined with the millions of patients that could benefit from this treatment, creates an enormous potential demand for these compounds. Current treatments only halt the progression of plaque build-up however, a new class of drugs, most notably Apo AI Milano, has been shown to actually reduce plaque size. Apo AI is the major protein associated with high density lipoprotein (HDL), or "good cholesterol", whose function is to remove excess cholesterol from arteries. |
|
 |
|
Apo AI and Apo AI Milano are being produced by SemBioSys in genetically engineered safflower as a way to solve the manufacturing and dosing challenges that currently exist. Transgenic plants may be the only cost-effective production model for creating the large scale amounts needed of these life-saving drugs.
Recent Awards
|
|
|